A rapid and sensitive UHPLC-MS/MS method for the determination of ziyuglycoside I and its application in a preliminary pharmacokinetic study in healthy and leukopenic rats
- PMID: 31864212
- DOI: 10.1016/j.biopha.2019.109756
A rapid and sensitive UHPLC-MS/MS method for the determination of ziyuglycoside I and its application in a preliminary pharmacokinetic study in healthy and leukopenic rats
Abstract
Ziyuglycoside I (ZgI), one of the main active ingredients in the popular Diyushengbai tablet made from Sanguisorba officinalis L., has been proven to relieve leukopenia clinically. However, to our knowledge, no studies have investigated the pharmacokinetics of either Diyushengbai tablet or ZgI in leukopenic vs. healthy individuals. In the present study, a rapid and sensitive UHPLC-MS/MS method was developed for detecting ZgI. On using this method on a novel cyclophosphamide-induced leukopenia model, we investigated differences in the pharmacokinetic characteristics of ZgI between leukopenic and normal rats. Chromatographic separation of ZgI and glycyrrhetinic acid (IS) was achieved via gradient elution in 0.5 min, and the total run time lasted for 5 min. Methodological validation results presented a good accuracy (102.6 %-110.8 %) and precision (% RSD ≤ 13.8) with a limit of quantitation of 0.5 ng/mL. Pharmacokinetic results showed a significantly shortened peak time (Tmax) (0.93 vs. 0.33 h) while a remarkably decreased maximum concentration (Cmax) (7.96 vs. 3.40 ng/L) in the 20 mg/kg leukopenia group in comparison with those in the 20 mg/kg normal group. In addition, a prolonged elimination half-life (t1/2β) was observed in the 20 mg/kg leukopenia group (5.02 vs. 18.51 h). We observed similar trends in the 5 mg/kg oral dosing treatment and control groups, except for Cmax, which did not differ between the groups. We did not find pharmacokinetic differences in ZgI between the two leukopenia groups. Thus, the pharmacokinetic parameters of ZgI (e.g., Tmax, Cmax, and T1/2β) changed based on the presence of a leukopenic state. This study may provide guidance for the development of ZgI as an agent for the treatment of leukopenia.
Keywords: Leukopenia; Pharmacokinetics; Sanguisorba officinalis L.; UHPLC-MS/MS; Ziyuglycoside I.
Copyright © 2019 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.
Similar articles
-
Comparison of the pharmacokinetic profiles of 13 phenolic acids and 6 triterpenes in normal and leukopenia rats after oral administration of Sanguisorba officinalis L. extract by LC-MS/MS.J Sep Sci. 2020 Nov;43(22):4103-4122. doi: 10.1002/jssc.202000514. Epub 2020 Oct 14. J Sep Sci. 2020. PMID: 32909652
-
Simultaneous Determination and Pharmacokinetics Study of Three Triterpenes from Sanguisorba officinalis L. in Rats by UHPLC-MS/MS.Molecules. 2022 Aug 24;27(17):5412. doi: 10.3390/molecules27175412. Molecules. 2022. PMID: 36080179 Free PMC article.
-
Development and Validation of a Novel UHPLC-MS/MS Method for the Quantification of Plinabulin in Plasma and Its Application in a Pharmacokinetic Study with Leukopenic Rats.Pharmaceuticals (Basel). 2023 Aug 14;16(8):1153. doi: 10.3390/ph16081153. Pharmaceuticals (Basel). 2023. PMID: 37631067 Free PMC article.
-
Simultaneous Determination and Pharmacokinetics Study of Six Triterpenes in Rat Plasma by UHPLC-MS/MS after Oral Administration of Sanguisorba officinalis L. Extract.Molecules. 2018 Nov 15;23(11):2980. doi: 10.3390/molecules23112980. Molecules. 2018. PMID: 30445715 Free PMC article.
-
Pharmacokinetics of four tannin compounds from Sanguisorba officinalis L. before and after processing by ultra-high-performance liquid chromatography-tandem mass spectrometry.J Sep Sci. 2024 Feb;47(4):e2300803. doi: 10.1002/jssc.202300803. J Sep Sci. 2024. PMID: 38403460
Cited by
-
A Comprehensive Review of Genus Sanguisorba: Traditional Uses, Chemical Constituents and Medical Applications.Front Pharmacol. 2021 Sep 20;12:750165. doi: 10.3389/fphar.2021.750165. eCollection 2021. Front Pharmacol. 2021. PMID: 34616302 Free PMC article. Review.
-
The development and validation of a sensitive HPLC-MS/MS method for the quantitative and pharmacokinetic study of the seven components of Buddleja lindleyana Fort.RSC Adv. 2021 Jul 28;11(42):26016-26028. doi: 10.1039/d1ra04154a. eCollection 2021 Jul 27. RSC Adv. 2021. PMID: 35479475 Free PMC article.
-
Pharmacokinetic Study of Four Major Bioactive Components of Liandan Xiaoyan Formula in Ulcerative Colitis and Control Rats Using UPLC-MS/MS.Front Pharmacol. 2022 Jul 4;13:936846. doi: 10.3389/fphar.2022.936846. eCollection 2022. Front Pharmacol. 2022. PMID: 35860031 Free PMC article.
-
Branched-Chain Amino Acids Catabolism Pathway Regulation Plays a Critical Role in the Improvement of Leukopenia Induced by Cyclophosphamide in 4T1 Tumor-Bearing Mice Treated With Lvjiaobuxue Granule.Front Pharmacol. 2021 Oct 25;12:657047. doi: 10.3389/fphar.2021.657047. eCollection 2021. Front Pharmacol. 2021. PMID: 34759816 Free PMC article.
-
Comparison of Pharmacokinetic Profiles of 14 Major Bioactive Components in Normal and Arthritic Model Rats after Oral Administration of Angelicae pubescentis Radix by UPLC-MS/MS.Evid Based Complement Alternat Med. 2022 Aug 16;2022:8379921. doi: 10.1155/2022/8379921. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 36016676 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
